Consun Pharma Repurchases 112,000 Shares; Treasury Stock Rises to 0.11% of Issued Capital

Bulletin Express06-04

Consun Pharmaceutical Group Limited (Consun Pharma) disclosed that it repurchased 112,000 ordinary shares on 4 June 2026 via on-market transactions on the Hong Kong Stock Exchange. The buyback was executed at prices between HKD 14.02 and HKD 14.22 per share, for a total consideration of HKD 1.58 million, implying a volume-weighted average cost of HKD 14.13 per share.

Following the transaction, Consun Pharma’s outstanding share count (excluding treasury shares) declined by 0.0133% to 840.65 million shares, while treasury shares rose from 789,000 to 901,000. The company’s total issued share capital, including treasury shares, remains unchanged at 841.55 million shares.

The repurchase forms part of the mandate approved by shareholders on 26 May 2026, which authorises the company to buy back up to 84.12 million shares. To date, Consun Pharma has repurchased 557,000 shares under this mandate, equivalent to 0.6621% of the issued share base on the mandate date.

In accordance with Hong Kong listing rules, Consun Pharma is subject to a moratorium on issuing new shares or disposing of treasury shares until 4 July 2026.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1182978706?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-04 18:05","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1182978706","market":"us","top_or_hot":-1,"title":"Consun Pharma Repurchases 112,000 Shares; Treasury Stock Rises to 0.11% of Issued Capital","media":"Bulletin Express","content":"<p>Consun Pharmaceutical Group Limited (Consun Pharma) disclosed that it repurchased 112,000 ordinary shares on 4 June 2026 via on-market transactions on the Hong Kong Stock Exchange. The buyback was executed at prices between HKD 14.02 and HKD 14.22 per share, for a total consideration of HKD 1.58 million, implying a volume-weighted average cost of HKD 14.13 per share.</p>\n<p>Following the transaction, Consun Pharma’s outstanding share count (excluding treasury shares) declined by 0.0133% to 840.65 million shares, while treasury shares rose from 789,000 to 901,000. The company’s total issued share capital, including treasury shares, remains unchanged at 841.55 million shares.</p>\n<p>The repurchase forms part of the mandate approved by shareholders on 26 May 2026, which authorises the company to buy back up to 84.12 million shares. To date, Consun Pharma has repurchased 557,000 shares under this mandate, equivalent to 0.6621% of the issued share base on the mandate date.</p>\n<p>In accordance with Hong Kong listing rules, Consun Pharma is subject to a moratorium on issuing new shares or disposing of treasury shares until 4 July 2026.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Consun Pharma Repurchases 112,000 Shares; Treasury Stock Rises to 0.11% of Issued Capital</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nConsun Pharma Repurchases 112,000 Shares; Treasury Stock Rises to 0.11% of Issued Capital\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-06-04 18:05</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Consun Pharmaceutical Group Limited (Consun Pharma) disclosed that it repurchased 112,000 ordinary shares on 4 June 2026 via on-market transactions on the Hong Kong Stock Exchange. The buyback was executed at prices between HKD 14.02 and HKD 14.22 per share, for a total consideration of HKD 1.58 million, implying a volume-weighted average cost of HKD 14.13 per share.</p>\n<p>Following the transaction, Consun Pharma’s outstanding share count (excluding treasury shares) declined by 0.0133% to 840.65 million shares, while treasury shares rose from 789,000 to 901,000. The company’s total issued share capital, including treasury shares, remains unchanged at 841.55 million shares.</p>\n<p>The repurchase forms part of the mandate approved by shareholders on 26 May 2026, which authorises the company to buy back up to 84.12 million shares. To date, Consun Pharma has repurchased 557,000 shares under this mandate, equivalent to 0.6621% of the issued share base on the mandate date.</p>\n<p>In accordance with Hong Kong listing rules, Consun Pharma is subject to a moratorium on issuing new shares or disposing of treasury shares until 4 July 2026.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"01681","symbol_name":"康臣药业","start_time":0,"source_url":"","article_id":"1182978706","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1182978706","pubTimestamp":1780567506,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"Consun Pharmaceutical Group Limited (Consun Pharma) disclosed that it repurchased 112,000 ordinary shares on 4 June 2026 via on-market transactions on the Hong Kong Stock Exchange. The buyback was...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"01681":"康臣药业"},"translate_title":"康臣药业回购11.2万股；库存股升至已发行资本的0.11%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01681":1},"content_text":"Consun Pharmaceutical Group Limited (Consun Pharma) disclosed that it repurchased 112,000 ordinary shares on 4 June 2026 via on-market transactions on the Hong Kong Stock Exchange. The buyback was executed at prices between HKD 14.02 and HKD 14.22 per share, for a total consideration of HKD 1.58 million, implying a volume-weighted average cost of HKD 14.13 per share.\nFollowing the transaction, Consun Pharma’s outstanding share count (excluding treasury shares) declined by 0.0133% to 840.65 million shares, while treasury shares rose from 789,000 to 901,000. The company’s total issued share capital, including treasury shares, remains unchanged at 841.55 million shares.\nThe repurchase forms part of the mandate approved by shareholders on 26 May 2026, which authorises the company to buy back up to 84.12 million shares. To date, Consun Pharma has repurchased 557,000 shares under this mandate, equivalent to 0.6621% of the issued share base on the mandate date.\nIn accordance with Hong Kong listing rules, Consun Pharma is subject to a moratorium on issuing new shares or disposing of treasury shares until 4 July 2026.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"shareholding,SGX","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.43.1","shortVersion":"4.43.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1182978706","isCrawlerRequest":true}